This company is no longer in business. Investors can get details about any potential exits or failures here.

Akibah Health

Akibah Health

Early Stage

The world's first OtterBox-enabled, smartphone case glucometer!

The world's first OtterBox-enabled, smartphone case glucometer!


Raised to Date: Raised: $72,533

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Fitness & Wellness

Tech Sector


Distribution Model




Capital Intensity



San Jose, California

Business Type

High Growth

Akibah Health, with a pre-money valuation of $5.96 million, is raising funds on StartEngine. The company has created GluCase, an all-in-one diabetes management system. The system is OtterBox-enabled, encased in a smartphone case, and integrated as a glucose monitoring kit and Bluetooth module. Akibah Health works on a monthly subscription model wherein customers receive a GluCase, monthly supply of test strips, and access to a supporting mobile app. The company was founded by Fathi Abdelsalam and has already raised over $500,000 in its seed round of funding. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $1,070,000. Akibah Health has already fulfilled hundreds of pre-order sales in 2018 and is all ready to change diabetes patients’ lives.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 12/12/2019
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article


Akibah Health has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected into the top 10%-20% of our due diligence funnel. If you have questions regarding our deal diligence and selection methodology, please reach out to


Next Section: Problem


Approximately 425 million people worldwide have diabetes, which accounts for 12% of the world’s health care expenditures. According to the CDC (Centers for Disease Control) over 30 million Americans are living with diabetes. It is estimated 1 in 4 Americans living with diabetes do not know they have it.

To properly manage diabetes, patients must take their blood glucose levels at least daily and sometimes multiple times a day. This requires carrying a cumbersome, expensive device, testing strips, power cords, connection cords, etc. Along with the hassle of the daily requirements of managing diabetes, carrying the equipment is an additional burden. 

What if there was a way to integrate the physical diabetes management tools into something we could not leave home without?

Next Section: Solution


Akibah Health cleverly solves the logistics dilemma of monitoring glucose levels in diabetic patients. Its flagship GluCase product combines the industry-leading OtterBox smartphone case with a glucose meter and a slot for testing strips. In addition to the physical convenience and functionality of an OtterBox case for reading glucose levels, the GluCase includes a powerful application that tracks levels and provides helpful tips on how to improve their health management. The application is connected to a third-party diabetes management provider Akibah has contracted with to serve their patients. 

The application is part of a separate monthly subscription service Akibah plans to charge customers for $29/month. The service includes diabetes management through the application which has access to a live professional. Additionally, the subscription includes a monthly supply of testing strips which are shipped to the customer each month. This follows the successful myriad of popular subscription services that are flooding our mailboxes each month.

At this point, Akibah is committed to data privacy on the rich data it will collect on customers. In the future, once it reaches critical mass, Akibah intends to use the data to improve diabetes management for its patients. While data privacy protection is admirable, diabetic management data paired with lifestyle behavior is valuable. In the future, Akibah could ethically share the data it collects in a manner that will advance the care of its patients.

Next Section: Other


GluCase customers are the millions of people worldwide who have diabetes. GluCase will initially focus its channel strategy on selling through endocrinology and primary care practices, concentrating on the 1.5 million newly diagnosed diabetes patients in the US each year. These newly diagnosed patients will be educated on how to manage their condition and GluCase will be there to provide an easy device to pop onto their mobile phone, and a monthly subscription service to ensure they have the necessary testing strips to properly manage their diabetes. GluCase appeals to anyone who has diabetes and carries a smartphone wherever they go.

Next Section: Other


GluCase competes within a crowded field of glucose monitoring devices. The closest competitors are Pops!One, Glooko, iHealth, Dario and OneDrop. These are all within GluCase’s price point, wireless, and provide a physical dashboard on a smartphone to monitor a patient’s care. Some of the dashboards link up to real-time communication with a medical professional. What makes GluCase unique is its seamless integration into a smartphone case so there is no need to remember anything other than a smartphone.

All the above competitors are already out in the marketplace. iHealth has an existing suite of popular health care products such as temperature, blood pressure, etc., products that integrate with its smartphone application but require ancillary devices to plug into the smartphone.

Next Section: Other


Fathi Abdelsalam – Founder and CEO – Founded Akibah Health while finishing his graduate degree in Public Administration at Cornell University. Prior to graduate school, Mr. Abdelsalam spent six years at the US patent office as a patent examiner. After graduate school, he began working on Akibah Health. He kicked it off by spending three months at the prestigious TechStars accelerator. Since TechStars, he has been the entrepreneur in residence in Chili, Puerto Rico, Switzerland, and Detroit. All these diverse geographic experiences have likely helped shaped his international strategy for Akibah.

Next Section: Why We Like it

Why We Like it


  • Patents: Akibah Health has two pending patents on its flagship product, GluCase. It also has two registered trademarks. 




  • OtterBox Partnership: GluCase is unique in a crowded field of diabetes management tools because of its exclusive partnership with the world’s bestselling smartphone case, OtterBox. Newly diagnosed diabetes patients are likely to be overwhelmed by the sea of diabetes monitoring devices and attracted to a known brand such as OtterBox. Plus, once Glucose has its commercial launch, OtterBox will prominently display the Glucose product on its website.




  • Larry Ellingson – Strategist – Mr. Ellingson provides tremendous legitimacy and industry opportunity to Akibah. Mr. Ellingson is the former chairman of the American Diabetes Association. He also spent thirty years at Eli Lilly as executive director of worldwide diabetes care. According to his LinkedIn page, he currently holds six positions at various organizations related to diabetes and cancer care. Although Mr. Ellingson is listed in Akibah’s StartEngine listing, Mr. Ellingson does not list Akibah on his LinkedIn page nor as an officer in the SEC filings.




  • TechStars: Mr. Abdelsalam completed the prestigious TechStars incubator program five years ago. TechStars is consistently listed in the top five incubator programs. Incubator programs that began in the mid-2000s have helped launch some of the most recognizable startups in the past ten years. TechStars provides Akibah health with resources, networks, and mentorships necessary to launch a startup.



Next Section: Other

The Rating: Deal To Watch

According to the Mayo Clinic, the number one issue with diabetic management is medication adherence and management. This means patients must monitor and track their glucose levels along with diet and exercise. Currently, the best practice is a separate device to test glucose levels. Some of the more modern diabetic monitoring devices link to an application that will guide patients to adjust how they are managing their diabetes. There is no device on the market which seamlessly integrates into a smartphone.

Mr. Abdelsalam spoke passionately about the many focus groups the company has conducted worldwide to ensure GluCase met the needs of diabetic patients. The launch plan is to sell GluCase through endocrinologists and primary care doctors, yet there are no formally signed agreements. GluCase will be produced in South Korea, and ready to ship in late 2020. It has taken the company five years to get to this point. 

When I asked Mr. Abdelsalam why KingsCrowd investors should bet on Akibah, with him as the CEO, he enthusiastically declared a long list of credentials. This is the first time Mr. Abdelsalam has led a company in his professional career. Then again, there are plenty of examples of entrepreneurs who were wildly successful in their first venture. Mr. Abdelsalam has secured a partnership with the industry giant, OtterBox and convinced Larry Ellingson, former Chairman of the American Diabetes Association to join the team. Those are two significant differentiators. While diabetes care is a crowded market, the number of patients with diabetes is sadly forecasted to continue to grow worldwide, thus creating room for innovative products such as GluCase.  

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Akibah Health on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $5,960,000
Price per Share: $0.56

Follow company

Follow Akibah Health on StartEngine

Buy Akibah Health's Deal Report

Warning: according to the close date for this deal, Akibah Health may no longer be accepting investments.

Akibah Health Deal Report

Get KingsCrowd’s comprehensive report on Akibah Health including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Akibah Health is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Akibah Health deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge